The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways

被引:5
|
作者
Ye, Yongju [1 ]
Zhou, Weimei [2 ]
Ren, Yuefang [3 ]
Lu, Jiali [3 ]
Chen, Aixue [4 ]
Jin, Ruiying [5 ]
Xuan, Feilan [6 ]
机构
[1] Lishui Hosp Tradit Chinese Med, Dept Gynaecol, Lishui, Peoples R China
[2] Jiaojiang Maternal & Child Hlth Hosp, Dept Ultrasound, Taizhou, Peoples R China
[3] Huzhou Matern & Child Hlth Care Hosp, Dept Gynecol, Huzhou, Peoples R China
[4] Changxing Peoples Hosp Chongming Dist, Dept Gynecol, Shanghai, Peoples R China
[5] Jiaojiang Maternal & Child Hlth Hosp, Dept Gynaecol, Taizhou, Peoples R China
[6] Zhejiang Chinese Med Univ, Dept Obstet & Gynecol, Hangzhou TCM Hosp, Hangzhou, Peoples R China
关键词
Polycystic ovary syndrome; guizhi fuling wan; rosiglitazone; PI3K/AKT/NF-kappa B pathway; Nrf2/HO-1; pathway; OXIDATIVE STRESS; GRANULOSA-CELLS; PCOS; INFLAMMATION; ASSOCIATION; AUTOPHAGY;
D O I
10.1080/09513590.2023.2254848
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: GuizhiFulingWan (GFW) has been reported to be effective against polycystic ovary syndrome (PCOS) by possessing oxidative stress and inflammation which related to PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathway. This study aims to probe the effects and mechanisms of GFW combined with rosiglitazone on PCOS via PI3K/AKT/NF-kappa B and Nrf2/HO-1 pathways. Methods: A rat PCOS model established by dehydroepiandrosterone (DHEA) injection. The experiment was allocated to control, DHEA, GFW, rosiglitazone, GFW + rosiglitazone groups. Treatment for 30 days, we monitored weight and ovarian weight of rats. Fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), lipid metabolism indexes, estrous cycle and sex hormone-, inflammation-, oxidative stress-related factors were examined. Hematoxylin&eosin staining assessed ovarian tissue pathological changes. Western blot determined PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathways-related markers. Results: GFW and rosiglitazone treatment suppressed body weight and ovarian weight in PCOS rats. They also decreased FBG, FINS, HOMA-IR while inhibited total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and enhanced high-density lipoprotein (HDL). They ameliorated estrous cycle, ovarian histological changes and follicular development. They restrained testosterone (T), luteinizing hormone (LH) and accelerated estradiol (E2), progesterone (P), follicle stimulating hormone (FSH). They inhibited glutathione peroxidase (GSH-Px), malondialdehyde (MDA), superoxide dismutase (SOD) in serum while increased GSH-Px, SOD and decrease MDA in ovarian tissues. They reduced C-reactive protein, interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-1 beta levels. GFW and rosiglitazone co-intervention regulated PI3K/AKT/NF-kappa B and Nrf2/HO-1 pathways in PCOS rats. Conclusion: GFW alleviated ovarian dysfunction in PCOS rats, which may be related to the PI3K/AKT/NF-kappa B, Nrf2/HO-1 pathways.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-κB and Nrf2/HO-1 pathways
    Jing Ye
    Hongmei Piao
    Jingzhi Jiang
    Guangyu Jin
    Mingyu Zheng
    Jinshi Yang
    Xiang Jin
    Tianyi Sun
    Yun Ho Choi
    Liangchang Li
    Guanghai Yan
    Scientific Reports, 7
  • [2] Polydatin inhibits mast cell-mediated allergic inflammation by targeting PI3K/Akt, MAPK, NF-κB and Nrf2/HO-1 pathways
    Ye, Jing
    Piao, Hongmei
    Jiang, Jingzhi
    Jin, Guangyu
    Zheng, Mingyu
    Yang, Jinshi
    Jin, Xiang
    Sun, Tianyi
    Choi, Yun Ho
    Li, Liangchang
    Yan, Guanghai
    SCIENTIFIC REPORTS, 2017, 7
  • [3] Nrf2/HO-1, NF-κB and PI3K/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats
    Elbaset, Marawan A.
    Mohamed, Bassim M. S. A.
    Hessin, Alyaa
    Abd El-Rahman, Sahar S.
    Esatbeyoglu, Tuba
    Afifi, Sherif M.
    Fayed, Hany M.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (03)
  • [4] Manganese-Based Nanozyme Alleviates Acute Kidney Injury via Nrf2/HO-1 and PI3K/Akt/NF-κB Signaling Pathways
    Zhang, Yang
    Wang, Han
    Liu, Ke
    Sun, Ruimeng
    Wang, Yurou
    Guo, Jiayu
    Zhou, Wenxiang
    Zheng, Haoran
    Qi, Yanfei
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2025, 11 (03): : 1751 - 1764
  • [5] Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway
    Liu, Min
    Zhu, Hongqiu
    Zhu, Ying
    Hu, Xiaodan
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 270
  • [6] Antihepatocarcinoma Effect of Portulaca oleracea L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB Pathway
    Zheng Guoyin
    Peng Hao
    Li Min
    Gu Wei
    Chen Zhe
    Ling Changquan
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 2017
  • [7] Role of Nrf2/HO-1 and PI3K/Akt Genes in the Hepatoprotective Effect of Cilostazol
    Hassan, Marwa
    Ibrahim, Mohamad A.
    Hafez, Heba M.
    Mohamed, Mervat Z.
    Zenhom, Nagwa M.
    Abd Elghany, Hend M.
    CURRENT CLINICAL PHARMACOLOGY, 2019, 14 (01): : 61 - 67
  • [8] The effect of sitagliptin combined with rosiglitazone on autophagy and inflammation in polycystic ovary syndrome by regulating PI3K/AKT/mTOR and TLR4/NF-κB pathway
    Ren, Yuefang
    Ye, Yongju
    Xuan, Feilan
    Chen, Aixue
    Jin, Ruiying
    Zhou, Weimei
    Lu, Jiali
    REPRODUCTIVE BIOLOGY, 2023, 23 (02)
  • [9] Antidepressant mechanism of catalpol: Involvement of the PI3K/Akt/Nrf2/HO-1 signaling pathway in rat hippocampus
    Wang, Junming
    Chen, Rongxing
    Liu, Chen
    Wu, Xiaohui
    Zhang, Yueyue
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 909
  • [10] Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways
    Huang, Jinxiang
    Li, Qixuan
    Wang, Hongxiang
    Zhang, Shuai
    Zhou, Xiaorong
    Huang, Fang
    Chen, Juxiang
    Xu, Luning
    Kang, Dezhi
    JOURNAL OF GENE MEDICINE, 2025, 27 (02):